Skip to main content
OpenTrials
Completed

NCT Number: NCT02086253

Role of Endothelin-1 in Flow-mediated Dilatation

Endothelial dysfunction of conduit arteries contributes to the increased morbidity and cardiovascular mortality in patients with essential hypertension and appears increasingly as an independent therapeutic target. We have shown previously that besides a decrease in the availability of NO and other endothelium-derived vasodilators factors, the epoxyeicosatrienoic acids, an increase in the vasoconstrictor endothelin-1 (ET-1) may play a role in the pathophysiology of this endothelial dysfunction. Indeed, the local concentrations of endothelin-1 during the endothelium-dependent dilation of the radial artery in response to a sustained increase in blood flow decreased significantly in healthy volunteers controls but not in hypertensive patients. This lack of adaptation of the endothelinergic system could be due to a decreased clearance of endothelin-1 by endothelial ETB receptors, potentiating the vasoconstrictor action of endothelin-1 mediated by ETA receptor activation at the muscular level. However, to validate this hypothesis , it is needed to demonstrate the physiological role of ETA receptor and ETB in sustained flow-mediated dilatation of conduit arteries.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Conditions

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

CHU - Hôpitaux de Rouen

Rouen, Normandy, 76031, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male, Caucasian, aged 18 to 35 years
  • Non-Smoking
  • Resting heart rate> 50 and <90 bpm
  • SBP <140 mmHg and DBP <90 mm Hg at rest in the supine position for 10 minutes
  • Normal ECG

Exclusion criteria

  • Known allergy
  • Intolerance to glyceryl trinitrate
  • Intolerance to lidocaine
  • Family history of hypertension
  • Excessive alcohol consumption ( more than 50 g / day)
  • Addiction or presumption of illicit drug use
  • Subject refusing blood samples for serology of hepatitis B , C and HIV
  • History of illness or psychological or sensory abnormality that may prevent the subject to understand the requirements for participation in the protocol or prevents giving informed consent
  • Metabolic or endocrine disease
  • Immunological diseases
  • Renal or hepatic impairment
  • Ischemic or obstructive heart disease
  • Neoplastic disease
  • Gastrointestinal disease
  • Neurological disease , intracranial hypertension , seizure disorders
  • Compulsive overeating , bulimia, anorexia
  • Severe psychiatric illness
  • Presence of a clinically significant abnormality in laboratory tests carried out at the inclusion visit .
  • HBs Ag , HCV Ab , Ac HIV 1 or HIV 2 positive .
  • The use of any drug in the range of less than 5 half-life time, in particular betablockers, sildenafil, cimetidine, amiodarone .

Treatment and study plan

BQ-788 and/or BQ-123

Drug

Primary outcomes

  1. Effect of ETB receptor blockade on flow-mediated dilatation

    Time frame: One hour after BQ-788 brachial infusion

    This study will evaluate the effect of the ETB receptor blockade on the magnitude of the flow-mediated dilatation of the radial artery in response to distal skin heating in 8 healthy subjects. Radial artery diameter and blood flow will be measured by high-resolution echotracking coupled to Doppler.

Secondary outcomes

  1. Effect of ETA and ETA/ETB receptor blockade on flow-mediated dilatation

    Time frame: One hour after BQ-123 alone or with BQ-788 brachial infusion

    This study will evaluate the effect of ETA receptor and combined ETA/ETB receptor blockade on the magnitude of the flow-mediated dilatation of the radial artery in response to distal skin heating in 8 healthy subjects. Radial artery diameter and blood flow will be measured by high-resolution echotracking coupled to Doppler.

  2. Effect of ETA and/or ETB receptor blockade on ET-1, NO and EET bioavailability

    Time frame: One hour after BQ-788 and/or BQ-123 brachial infusion

    This study will evaluate the effect of ETA and/or ETB blockade on the variations in the local concentrations of ET-1, NO and EETs during sustained flow-mediated dilation in 8 healthy subjects. For this purpose, local blood samples will be drawn before (34°C) and at the end of hand skin heating (44°C). Plasma nitrite, indicator of NO availability will be quantified by chemiluminescence.Plasma EETs will be quantified by LC-MS. Plasma ET-1 will be quantified with an immunoassay.

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Registry information

Official study title

Role of Endothelin-1 in Mediating Flow-mediated Dilatation of Conduit Arteries During Sustained Hyperemic Stimulation

Acronym: Endothelin

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Mar 13, 2014
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.